The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases

David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John Peter Bradford, Joan H. Schiller, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug authorization. Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering. We must replace current compliance-centered regulation (appropriate for nonlethal diseases like acne) with "progress-centered regulation" in lethal diseases, where the overarching objective must be rapid, inexpensive development of effective new therapies. We need to (i) reduce expensive, time-consuming preclinical toxicology and pharmacology assessments, which add little value; (ii) revamp the clinical trial approval process to make it fast and efficient; (iii) permit immediate multiple-site trial activation when an eligible patient is identified ("just-in-time" activation); (iv) reduce the requirement for excessive, low-value documentation; (v) replace this excessive documentation with sensible postmarketing surveillance; (vi) develop pragmatic investigator accreditation; (vii) where it is to the benefit of the patient, permit investigators latitude in deviating from protocols, without requiring approved amendments; (viii) confirm the value of predictive biomarkers before requiring the high costs of IDE/CLIA compliance; and (ix) approve agents based on high phase I-II response rates in defined subpopulations, rather than mandating expensive, time-consuming phase III trials.

Original languageEnglish (US)
Pages (from-to)4561-4568
Number of pages8
JournalClinical Cancer Research
Issue number20
StatePublished - Oct 15 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases'. Together they form a unique fingerprint.

Cite this